These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11071627)

  • 21. Hematologic response to hydroxyurea therapy in children with beta-thalassemia major.
    Mtvarelidze Z; Kvezereli-Kopadze A; Kvezereli-Kopadze M; Mestiashvili I
    Georgian Med News; 2008 Mar; (156):91-4. PubMed ID: 18403819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum erythropoietin and erythropoiesis in high- and low-fetal hemoglobin beta-thalassemia intermedia patients.
    Galanello R; Barella S; Turco MP; Giagu N; Cao A; Dore F; Liberato NL; Guarnone R; Barosi G
    Blood; 1994 Jan; 83(2):561-5. PubMed ID: 7506955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant human erythropoietin therapy in a transfusion-dependent beta-thalassemia major patient.
    Makis AC; Chaliasos N; Hatzimichael EC; Bourantas KL
    Ann Hematol; 2001 Aug; 80(8):492-5. PubMed ID: 11563599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term hydroxyurea therapy in beta-thalassaemia patients.
    de Paula EV; Lima CS; Arruda VR; Alberto FL; Saad ST; Costa FF
    Eur J Haematol; 2003 Mar; 70(3):151-5. PubMed ID: 12605659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE-β thalassaemia.
    Biswas S; Nag A; Ghosh K; Ray R; Roy K; Bandyopadhyay A; Bhattacharyya M
    Ann Hematol; 2019 Feb; 98(2):289-299. PubMed ID: 30413899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxyurea in thalassemia intermedia--a promising therapy.
    Dixit A; Chatterjee TC; Mishra P; Choudhry DR; Mahapatra M; Tyagi S; Kabra M; Saxena R; Choudhry VP
    Ann Hematol; 2005 Jul; 84(7):441-6. PubMed ID: 15838670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of a transfusion preparation of newly formed red cells and standard washed red cell transfusions in patients with homozygous beta-thalassemia.
    Collins AF; Gonçalves-Dias C; Haddad S; Talbot R; Herst R; Tyler BJ; Zuber E; Blanchette VS; Olivieri NF
    Transfusion; 1994 Jun; 34(6):517-20. PubMed ID: 8023393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical transfusion-dependent humanized mouse model of beta thalassemia major.
    Huo Y; McConnell SC; Ryan TM
    Blood; 2009 May; 113(19):4763-70. PubMed ID: 19258591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress.
    Perrine SP; Castaneda SA; Boosalis MS; White GL; Jones BM; Bohacek R
    Ann N Y Acad Sci; 2005; 1054():257-65. PubMed ID: 16339673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study.
    Pasricha SR; Frazer DM; Bowden DK; Anderson GJ
    Blood; 2013 Jul; 122(1):124-33. PubMed ID: 23656728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isobutyramide therapy in patients with sickle cell anemia.
    Saleh AW; van Goethem A; Jansen R; Velvis HJ; Gu LH; Huisman TH
    Am J Hematol; 1995 Jul; 49(3):244-6. PubMed ID: 7541604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
    Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
    Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea.
    Dover GJ
    Ann N Y Acad Sci; 1998 Jun; 850():80-6. PubMed ID: 9668530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies.
    Sher GD; Ginder GD; Little J; Yang S; Dover GJ; Olivieri NF
    N Engl J Med; 1995 Jun; 332(24):1606-10. PubMed ID: 7753139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.
    Thompson AA; Walters MC; Kwiatkowski J; Rasko JEJ; Ribeil JA; Hongeng S; Magrin E; Schiller GJ; Payen E; Semeraro M; Moshous D; Lefrere F; Puy H; Bourget P; Magnani A; Caccavelli L; Diana JS; Suarez F; Monpoux F; Brousse V; Poirot C; Brouzes C; Meritet JF; Pondarré C; Beuzard Y; Chrétien S; Lefebvre T; Teachey DT; Anurathapan U; Ho PJ; von Kalle C; Kletzel M; Vichinsky E; Soni S; Veres G; Negre O; Ross RW; Davidson D; Petrusich A; Sandler L; Asmal M; Hermine O; De Montalembert M; Hacein-Bey-Abina S; Blanche S; Leboulch P; Cavazzana M
    N Engl J Med; 2018 Apr; 378(16):1479-1493. PubMed ID: 29669226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment.
    Singer ST; Kuypers FA; Olivieri NF; Weatherall DJ; Mignacca R; Coates TD; Davies S; Sweeters N; Vichinsky EP
    Ann N Y Acad Sci; 2005; 1054():250-6. PubMed ID: 16339672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the Xmn1-(G) γ polymorphism in β-thalassemia/hemoglobin E (HbE) and homozygous HbE patients with low and high levels of HbF.
    Prasing W; Odawara T; Traisathit P; Yamashiro Y; Hattori Y; Pornprasert S
    Int J Lab Hematol; 2015 Apr; 37(2):e25-8. PubMed ID: 25043956
    [No Abstract]   [Full Text] [Related]  

  • 39. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
    Alebouyeh M; Moussavi F; Haddad-Deylami H; Vossough P
    Ann Hematol; 2004 Jul; 83(7):430-3. PubMed ID: 14722738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Betibeglogene Autotemcel Gene Therapy for Non-β
    Locatelli F; Thompson AA; Kwiatkowski JL; Porter JB; Thrasher AJ; Hongeng S; Sauer MG; Thuret I; Lal A; Algeri M; Schneiderman J; Olson TS; Carpenter B; Amrolia PJ; Anurathapan U; Schambach A; Chabannon C; Schmidt M; Labik I; Elliot H; Guo R; Asmal M; Colvin RA; Walters MC
    N Engl J Med; 2022 Feb; 386(5):415-427. PubMed ID: 34891223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.